Stay updated on SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial
Sign up to get notified when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.

Latest updates to the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe update includes a minor site-version revision (Revision: v3.4.2) and removal of a government-operating-status notice; no study content, eligibility criteria, or results are affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedA government funding lapse notice was added and the revision tag updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedUI and metadata updates were applied: a 'Show glossary' toggle is now shown, and QC-related labels were updated to 'Last Update Submitted that Met QC Criteria' with a new 'Revision: v3.4.0'. The 'No FEAR Act Data' label is present and older variant labels were removed.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page shows a new revision label 'Revision: v3.3.4', replacing the previous 'v3.3.3', with no observed changes to core content, eligibility criteria, or contacts. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedFooter notes now show Revision: v3.3.3; the HHS Vulnerability Disclosure and Revision: v3.3.2 entries were removed.SummaryDifference0.1%

- Check91 days agoChange DetectedRevision: v3.3.2 was added and v3.2.0 was removed. This update does not modify the study details, eligibility criteria, endpoints, or other substantive content on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.